NEW YORK (GenomeWeb News) – The specialized genetics company Motif BioSciences Inc. is forming a new partnership with the Imperial College London aimed at deciphering the genetics of diabetes, obesity, and other related metabolic and cardiovascular disorders, the company announced today.
Motif, which is an Amphion Innovations partner company, plans to team up with Imperial College’s head of genomic medicine Philippe Froguel, who has extensive experience studying metabolic diseases. Once they receive appropriate permission, Motif plans to access genetic samples and clinical data that Froguel and his collaborators have collected in Morocco.
Using their genomic analysis tools and high density microarray technology, Motif hopes to identify genomic variants that predispose some individuals to diabetes, obesity, and other diseases. This, in turn, may reveal new druggable targets and molecular biomarkers, they said.
“This is Motif’s first major project in this field and we are excited to be working with such a highly respected, ground-breaking team,” Motif CEO Zaki Hosny said in a statement.